Damora Therapeutics, Inc. (DMRA): Total Assets
$260.53M
As of 2025-12-31
$543.64M
As of 2026-06-30
+52.7%
3-year compound annual growth
+8.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $260.53M | n/m | 2026-03-19, Balance as of period end |
| 2024-12-31 | $17.13M | -55.2% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $38.23M | -47.8% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $73.19M | -40.1% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $122.22M | -28.8% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $171.60M | +203.1% | 2022-02-17, Balance as of period end |
| 2019-12-31 | $56.61M | n/a | 2021-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $260.53M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $259.15M | -31.5% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $257.59M | +116.2% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $256.85M | -1.8% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $255.88M | +9.7% |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $266.97M | -21.7% |
| Savara Inc (SVRA) | 2025-12-31 | $253.44M | +19.1% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $271.15M | -21.2% |
Compare DMRA, NATR, PHAT, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗